Patient-derived SEPTIN6 mutations point to a stem cell defect behind congenital neutropenia
A rare inherited blood disorder can look deceptively simple at the bedside: persistent neutropenia, repeated infections, and a marrow that fails to keep pace with demand. In this JCI Insight study, SEPTIN6 emerges as more than a structural cytoskeletal protein. The patient-derived mutations described here are tied to a deeper problem in hematopoiesis, one centered on hematopoietic stem cell senescence and the progression toward myelodysplasia.
The work builds on two pediatric patients previously identified with germline SEPT6 mutations, c.1282T>C and c.1282T>A, both presenting with congenital neutropenia and subsequent development of myelodysplastic syndrome. In one of those patients, an additional somatic mutation, c.43C>T, appeared at low allelic fraction in the bone marrow. Those genetic findings are not just cataloging exercises. They suggest that a single cytoskeletal pathway, when altered in a neomorphic fashion, can shape the fate of hematopoietic stem and progenitor cells over time.
The biology is striking. Septins are RAS-like GTP-binding proteins involved in cytoskeletal organization and cellular division. In healthy blood formation, that machinery matters at multiple levels: polarity, intracellular trafficking, mitotic fidelity, and the ability of stem cells to preserve self-renewal while generating mature myeloid cells. When that system is disturbed, the marrow may not simply produce fewer neutrophils; it may drift into a stress state that resembles premature aging at the stem cell level.
One sentence captures the central clinical concern: these mutations do not appear to produce only loss of function.
The title of the study makes the mechanistic claim explicit. These are neomorphic SEPTIN6 mutations, meaning the altered protein acquires a new or abnormal function rather than merely losing the old one. That distinction is important in a disorder like congenital neutropenia, because a neomorphic mutation can actively rewire cell behavior, not just impair it. In practical terms, a stem cell compartment pushed toward senescence cannot sustain normal granulopoiesis, and the marrow injury may create a foothold for dysplastic evolution.
The article’s framing also links congenital neutropenia and myelodysplasia as part of one biologic continuum rather than two separate diagnoses. Persistent failure of the stem cell pool can produce chronic neutropenia early in life, while the same exhausted compartment may later accumulate additional abnormalities that are compatible with myelodysplastic change. The low-level somatic SEPT6 variant detected in bone marrow from one patient fits that narrative of stepwise clonal pressure, although the text provided here does not extend to the full experimental detail.
The clinical relevance is immediate for hematologists and pediatric oncologists. When neutropenia is rooted in stem cell senescence, treatment decisions carry different implications than when the neutropenia is isolated, transient, or immune-mediated. A marrow disorder driven by an intrinsic genetic defect in stem cell maintenance raises concern for progression, surveillance needs, and the possibility that the patient’s hematopoietic reserve is compromised long before overt morphologic myelodysplasia appears.
The study also reinforces an important theme in inherited marrow failure syndromes: the phenotype may reflect not just cell shortage, but altered stem cell identity. Senescence is not a passive endpoint. It is a programmed response marked by loss of proliferative competence and functional exhaustion, and in the hematopoietic system that can ripple outward into reduced neutrophil output, impaired lineage balance, and vulnerability to clonal escape. In that setting, a mutation in a septin gene becomes clinically meaningful because it sits upstream of the stem cell behavior that determines whether the marrow can recover after routine physiologic stress.
This is a focused molecular study, but its implications are broad. Patients with congenital neutropenia and evolving marrow abnormalities often prompt the question of whether the problem lies in the niche, the lineage, or the stem cell itself. Here, the answer appears to sit squarely at the stem cell level. The pathologic thread running through the report is senescence, and senescence is a poor substrate for durable blood production.
The abstract available here identifies the genetic lesions and the disease context, but it leaves several clinically important details outside the visible text, including the full experimental readouts and the extent to which the patient-derived mutations altered stem cell function in model systems. Even so, the core message is already clear from the title and abstract framing: SEPTIN6 mutations can act as disease-driving lesions in congenital neutropenia and may help explain why some patients progress toward myelodysplasia.
For clinicians following children with unexplained neutropenia, the practical consequence is careful attention to inherited marrow failure genes that may not present with a textbook phenotype. A septin defect may leave a recognizable signature only after marrow stress has accumulated, and by then the biology has already shifted toward exhaustion rather than recovery.